Start your Trading & Investing Journey with us
Join our channel for Daily Free Trades with Live analysis on Youtube, Trade Setup with Important Levels, and Important Stock Market Updates
Goldline Pharmaceutical IPO Review - Issue Date, Price, GMP, Subscription, Allotment, Lot Size, and Details
Goldline Pharmaceutical Limited IPO : Key Performance Indicators, PE Ratio, EPS, ROE, ROCE & RoNW
The Company Key Performance Indicates the pre-issue EPS of ₹
4.1 and post-issue EPS of ₹
2.95 for FY25. The pre-issue P/E ratio is
10.49x,while the post-issue P/E ratio is
14.58x against the Industry P/E ratio is
18.26x The company's ROE for FY25 is
35.83% and RoNW is
27.37% The Annualised EPS is ₹
3.09x and P/E is
₹
13.93x , These metrics suggest that the IPO is Fully priced.
Key Performance Indicator
| KPI | Values |
|---|---|
| EPS Pre IPO (Rs.) | 4.1 |
| EPS Post IPO (Rs.) | 2.95 |
| Adjusted 12M EPS Post IPO (Rs.) | 3.09 |
| P/E Pre IPO | 10.49 |
| P/E Post IPO | 14.58 |
| Adjusted 12M P/E Post IPO | 13.93 |
| ROE | 35.83% |
| ROCE | 38.45% |
| P/BV | 3.47 |
| Debt/Equity | 1.5 |
| RoNW | 27.37% |
| EBITDA Margin | 20.78% |
| PAT Margin | 10.09% |
© 2022 CA Abhay Varn. All Rights Reserved Abhayvarn.com
